CASIA OpenIR
F-18-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Kong, Ziren1,2,3; Lin, Yusong4,11; Jiang, Chendan1,2; Li, Longfei4; Liu, Zehua4; Wang, Yuekun1,2; Dai, Congxin1,2; Liu, Delin1,2,3; Qin, Xuying2,6,10; Wang, Yu1; Liu, Zhenyu5,9; Cheng, Xin2,3; Tian, Jie5,7,8,9; Ma, Wenbin1,2
Source PublicationCANCER IMAGING
ISSN1740-5025
2019-08-19
Volume19Issue:1Pages:10
Corresponding AuthorCheng, Xin(pumch_chengxin@126.com) ; Tian, Jie(jie.tian@ia.ac.cn) ; Ma, Wenbin(mawb2001@hotmail.com)
AbstractBackground The methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter has emerged as a favorable independent prognostic and predictive biomarker in glioma. This study aimed to build a radiomics signature based on F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) for noninvasive measurement of the MGMT promoter methylation status in glioma. Methods One hundred and seven pathology-confirmed primary diffuse glioma patients were retrospectively included and randomly assigned to the primary (n = 71) or validation cohort (n = 36). The MGMT promoter methylation status was measured by pyrosequencing. A total of 1561 radiomics features were extracted from the three-dimensional region of interest (ROI) on the standard uptake value (SUV) maps that were generated from the original F-18-FDG PET data. A radiomics signature, a clinical signature and a fusion signature that combined the clinical and radiomics features together were generated. The performance of the three signatures was evaluated by receiver operating characteristic (ROC) curve analysis, and the patient prognosis was stratified based on the MGMT promoter methylation status and the signature with the best performance. Results Five radiomics features were selected to construct the radiomics signature, and displayed the best performance with area under the receiver operating characteristic (ROC) curve (AUC) reaching 0.94 and 0.86 in the primary and validation cohorts, respectively, which outweigh the performances of clinical signature and fusion signature. With a median follow-up time of 32.4 months, the radiomics signature stratified the glioma patients into two risk groups with significantly different prognoses (p = 0.04). Conclusions F-18-FDG-PET-based radiomics is a promising approach for preoperatively evaluating the MGMT promoter methylation status in glioma and predicting the prognosis of glioma patients noninvasively.
KeywordRadiomics FDG PET MGMT promoter methylation Glioma Prognosis
DOI10.1186/s40644-019-0246-0
WOS KeywordGLIOBLASTOMA ; TEMOZOLOMIDE ; SURVIVAL ; DISEASE ; PET
Indexed BySCI
Language英语
Funding ProjectChinese Academy of Medical Sciences Innovation Fund for Medical Sciences[2016-I2M-2-001] ; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences[2018-I2M-3-001] ; Fundamental Research Funds for the Central Universities[3332018029] ; National Natural Science Foundation of China[81772009] ; National Natural Science Foundation of China[81772012] ; Scientific and Technological Research Project of Henan Province[182102310162] ; Beijing Natural Science Foundation[7182109] ; Chinese Academy of Sciences[GJJSTD20170004] ; Chinese Academy of Sciences[QYZDJ-SSW-JSC005] ; Youth Innovation Promotion Association of Chinese Academy of Sciences[2019136]
Funding OrganizationChinese Academy of Medical Sciences Innovation Fund for Medical Sciences ; Fundamental Research Funds for the Central Universities ; National Natural Science Foundation of China ; Scientific and Technological Research Project of Henan Province ; Beijing Natural Science Foundation ; Chinese Academy of Sciences ; Youth Innovation Promotion Association of Chinese Academy of Sciences
WOS Research AreaOncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS SubjectOncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS IDWOS:000486718800001
PublisherBMC
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/27027
Collection中国科学院自动化研究所
Corresponding AuthorCheng, Xin; Tian, Jie; Ma, Wenbin
Affiliation1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, 1 Shuaifuyuan Wangfujing, Beijing, Peoples R China
2.Peking Union Med Coll, 1 Shuaifuyuan Wangfujing, Beijing, Peoples R China
3.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nucl Med, 1 Shuaifuyuan Wangfujing, Beijing, Peoples R China
4.Zhengzhou Univ, Collaborat Innovat Ctr Internet Healthcare, 75 Daxue Rd, Zhengzhou, Henan, Peoples R China
5.Chinese Acad Sci, Inst Automat, Key Lab Mol Imaging, 80 East Zhongguancun Rd, Beijing, Peoples R China
6.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuaifuyuan, Beijing, Peoples R China
7.Beihang Univ, Sch Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, 37 Xueyuan Rd, Beijing, Peoples R China
8.Xidian Univ, Sch Life Sci & Technol, Minist Educ, Engn Res Ctr Mol & Neuro Imaging, 266 Xinglong Sect,Xifeng Rd, Xian, Shaanxi, Peoples R China
9.Univ Chinese Acad Sci, 80 East Zhongguancun Rd, Beijing, Peoples R China
10.Tianjin Univ Sci & Technol, Key Lab Ind Microbiol, 1038 Dagu Nanlu, Tianjin, Peoples R China
11.Zhengzhou Univ, Sch Software, 75 Daxue Rd, Zhengzhou, Henan, Peoples R China
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Kong, Ziren,Lin, Yusong,Jiang, Chendan,et al. F-18-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma[J]. CANCER IMAGING,2019,19(1):10.
APA Kong, Ziren.,Lin, Yusong.,Jiang, Chendan.,Li, Longfei.,Liu, Zehua.,...&Ma, Wenbin.(2019).F-18-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.CANCER IMAGING,19(1),10.
MLA Kong, Ziren,et al."F-18-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma".CANCER IMAGING 19.1(2019):10.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Kong, Ziren]'s Articles
[Lin, Yusong]'s Articles
[Jiang, Chendan]'s Articles
Baidu academic
Similar articles in Baidu academic
[Kong, Ziren]'s Articles
[Lin, Yusong]'s Articles
[Jiang, Chendan]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Kong, Ziren]'s Articles
[Lin, Yusong]'s Articles
[Jiang, Chendan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.